Shennon Biotechnologies analyzes and manipulates a massive number of cells on the single-cell level to develop more effective treatments for human diseases. It functionally profiles millions of immune cells to find the best targets for cancer immunotherapy. Backed by Foundation Capital.
About the role
Our lead program is a trispecific TCE with dual tumor antigen targeting for small cell lung cancer. We are looking for someone to own CMC for it end to end, from the handoff out of discovery through to IND. This is a director-level role: hands-on and accountable for the work, not an executive building a function. The role reports on an interim basis to the Head of Research, pending the hire of the Chief Scientific Officer. Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- A PhD in a relevant discipline, or a BS or MS with at least 12 years in biologics CMC
- At least 1 antibody or antibody-derived protein taken from development candidate to IND with the CMC package filed, ideally a bispecific or multispecific rather than a monoclonal
- Direct experience selecting and managing CDMOs, including writing the RFP and reading the quotes critically
- Quality fluency sufficient to negotiate a quality agreement and to make a release decision on outsourced GMP material
- Module 3 authoring or QC, and enough regulatory fluency to defend the CMC section in an agency meeting
- Comfort working with CDMOs in China alongside US and European options, and a clear view on the trade-offs
More about this role
Shennon Biotechnologies is developing precision immunotherapies for solid tumors through an integrated technology platform spanning target discovery, ultra-high-throughput microfluidics-driven functional screening, computational therapeutic design and safety prediction. Where conventional discovery tests binders sequentially over months, Shennon's TCELERATOR platform profiles more than 10 million single-cell interactions at once, identifying functional leads in a single experiment. This unified engine is supported by proprietary human tumor datasets and an expanding network of academic and clinical collaborators. The Company is developing both antibody-based and TCR-based T-cell engagers designed to address surface and intracellular cancer targets. Its initial oncology pipeline includes programs in small cell lung cancer, ovarian cancer and hepatocellular carcinoma. ShennonBio is based in San Francisco.
Our lead program is a trispecific TCE with dual tumor antigen targeting for small cell lung cancer. We are looking for someone to own CMC for it end to end, from the handoff out of discovery through to IND.
This is a director-level role: hands-on and accountable for the work, not...
Browse similar: Startup jobs · Remote jobs · San Francisco Bay Area